Molecular screening for bladder cancer: Progress and potential

Anirban P. Mitra, Richard J Cote

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Carcinoma of the urinary bladder is a common malignancy and a major cause of morbidity and mortality in the western world. Current understanding of etiology, disease process, molecular characteristics and management principles make urothelial carcinoma an ideal candidate for screening. The capacity of traditional noninvasive diagnostic procedures such as microhematuria testing and urine cytology to be used as stand-alone screening techniques is limited, however. New qualitative and quantitative molecular screening modalities can detect cellular and subcellular alterations that are often exclusively associated with urothelial carcinoma. Such alterations can be detected in a noninvasive manner, using urine as a marker source, with reasonable sensitivity and specificity. Application of several molecular assays in conjunction with traditional screening methods has had promising results. We propose an evidence-based and risk-based approach to future bladder cancer screening. Such an approach would harness the reasonable sensitivity, ease of use and cost-effectiveness of microhematuria testing, plus the specificity of molecular tests, to target high-risk populations for screening. The ultimate goals are to identify susceptible individuals, detect bladder tumors before they invade using unobtrusive and cost-effective methods, and optimize surveillance strategies for long-term follow-up.

Original languageEnglish
Pages (from-to)11-20
Number of pages10
JournalNature Reviews Urology
Volume7
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Urinary Bladder Neoplasms
Carcinoma
Urine
Western World
Early Detection of Cancer
Cost-Benefit Analysis
Cell Biology
Urinary Bladder
Morbidity
Costs and Cost Analysis
Sensitivity and Specificity
Mortality
Population
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Molecular screening for bladder cancer : Progress and potential. / Mitra, Anirban P.; Cote, Richard J.

In: Nature Reviews Urology, Vol. 7, No. 1, 01.01.2010, p. 11-20.

Research output: Contribution to journalArticle

@article{2c1f5dba6b5c4f8e8f7b8eb5e8c1ff27,
title = "Molecular screening for bladder cancer: Progress and potential",
abstract = "Carcinoma of the urinary bladder is a common malignancy and a major cause of morbidity and mortality in the western world. Current understanding of etiology, disease process, molecular characteristics and management principles make urothelial carcinoma an ideal candidate for screening. The capacity of traditional noninvasive diagnostic procedures such as microhematuria testing and urine cytology to be used as stand-alone screening techniques is limited, however. New qualitative and quantitative molecular screening modalities can detect cellular and subcellular alterations that are often exclusively associated with urothelial carcinoma. Such alterations can be detected in a noninvasive manner, using urine as a marker source, with reasonable sensitivity and specificity. Application of several molecular assays in conjunction with traditional screening methods has had promising results. We propose an evidence-based and risk-based approach to future bladder cancer screening. Such an approach would harness the reasonable sensitivity, ease of use and cost-effectiveness of microhematuria testing, plus the specificity of molecular tests, to target high-risk populations for screening. The ultimate goals are to identify susceptible individuals, detect bladder tumors before they invade using unobtrusive and cost-effective methods, and optimize surveillance strategies for long-term follow-up.",
author = "Mitra, {Anirban P.} and Cote, {Richard J}",
year = "2010",
month = "1",
day = "1",
doi = "10.1038/nrurol.2009.236",
language = "English",
volume = "7",
pages = "11--20",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Molecular screening for bladder cancer

T2 - Progress and potential

AU - Mitra, Anirban P.

AU - Cote, Richard J

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Carcinoma of the urinary bladder is a common malignancy and a major cause of morbidity and mortality in the western world. Current understanding of etiology, disease process, molecular characteristics and management principles make urothelial carcinoma an ideal candidate for screening. The capacity of traditional noninvasive diagnostic procedures such as microhematuria testing and urine cytology to be used as stand-alone screening techniques is limited, however. New qualitative and quantitative molecular screening modalities can detect cellular and subcellular alterations that are often exclusively associated with urothelial carcinoma. Such alterations can be detected in a noninvasive manner, using urine as a marker source, with reasonable sensitivity and specificity. Application of several molecular assays in conjunction with traditional screening methods has had promising results. We propose an evidence-based and risk-based approach to future bladder cancer screening. Such an approach would harness the reasonable sensitivity, ease of use and cost-effectiveness of microhematuria testing, plus the specificity of molecular tests, to target high-risk populations for screening. The ultimate goals are to identify susceptible individuals, detect bladder tumors before they invade using unobtrusive and cost-effective methods, and optimize surveillance strategies for long-term follow-up.

AB - Carcinoma of the urinary bladder is a common malignancy and a major cause of morbidity and mortality in the western world. Current understanding of etiology, disease process, molecular characteristics and management principles make urothelial carcinoma an ideal candidate for screening. The capacity of traditional noninvasive diagnostic procedures such as microhematuria testing and urine cytology to be used as stand-alone screening techniques is limited, however. New qualitative and quantitative molecular screening modalities can detect cellular and subcellular alterations that are often exclusively associated with urothelial carcinoma. Such alterations can be detected in a noninvasive manner, using urine as a marker source, with reasonable sensitivity and specificity. Application of several molecular assays in conjunction with traditional screening methods has had promising results. We propose an evidence-based and risk-based approach to future bladder cancer screening. Such an approach would harness the reasonable sensitivity, ease of use and cost-effectiveness of microhematuria testing, plus the specificity of molecular tests, to target high-risk populations for screening. The ultimate goals are to identify susceptible individuals, detect bladder tumors before they invade using unobtrusive and cost-effective methods, and optimize surveillance strategies for long-term follow-up.

UR - http://www.scopus.com/inward/record.url?scp=75949121210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75949121210&partnerID=8YFLogxK

U2 - 10.1038/nrurol.2009.236

DO - 10.1038/nrurol.2009.236

M3 - Article

C2 - 20062071

AN - SCOPUS:75949121210

VL - 7

SP - 11

EP - 20

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

IS - 1

ER -